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Abstract
Bacillus cereus (B. cereus) is a pathogen in opportunistic infections. Here we show that Bacillus cereus sphingomyelinase (Bc-
SMase) is a virulence factor for septicemia. Clinical isolates produced large amounts of Bc-SMase, grew in vivo, and caused
death among mice, but ATCC strains isolated from soil did not. A transformant of the ATCC strain carrying a recombinant
plasmid containing the Bc-SMase gene grew in vivo, but that with the gene for E53A, which has little enzymatic activity, did
not. Administration of an anti-Bc-SMase antibody and immunization against Bc-SMase prevented death caused by the
clinical isolates, showing that Bc-SMase plays an important role in the diseases caused by B. cereus. Treatment of mouse
macrophages with Bc-SMase resulted in a reduction in the generation of H2O2 and phagocytosis of macrophages induced
by peptidoglycan (PGN), but no effect on the release of TNF-a and little release of LDH under our experimental conditions.
Confocal laser microscopy showed that the treatment of mouse macrophages with Bc-SMase resulted in the formation of
ceramide-rich domains. A photobleaching analysis suggested that the cells treated with Bc-SMase exhibited a reduction in
membrane fluidity. The results suggest that Bc-SMase is essential for the hydrolysis of SM in membranes, leading to
a reduction in phagocytosis.
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Introduction
B. cereus is well-known for its role as a mediator of food-borne
illness [1,2,3,4]. The microorganism, which forms spores, is
found worldwide in dust, air, and water [5]. Therefore, B. cereus
is ubiquitous in the hospital environment, indicating that
contamination of dressings, intravenous catheters, and linen
provides an opportunity for infection [5]. It is possible that B.
cereus is a pathogen of nosocomial infections transmitted via
towels, linen, and balloons to compromised patients [6,7]. In
recent years, there has been an increasing appreciation for its
potential as an opportunistic pathogen in immunocompromised
hosts [5,6,8,9]. The microorganism secretes a wide variety of
membrane-damaging toxins, phospholipases such as Bc-SMase,
phosphatidylinositol-specific phospholipase C (PIPLC) and phos-
phatidylcholine-specific phospholipase C (PCPLC), and hemoly-
sins such as cereolysin O, hemolysins and proteases
[3,10,11,12,13,14]. However, there has been little research into
the contributions of these enzymes and toxins to the infectious
diseases caused by B. cereus.
The SMase produced by the intracellular pathogen Listeria
ivanovii was shown to mediate bacterial escape from the
phagocytic vacuole following internalization, thereby promoting
intracellular survival and propagation [15]. Helicobacter pylori-
derived SMase was found to contribute toward cytotoxicity for
gastric cells [16]. b-Hemolysin containing SMase activity from
methicillin-resistant Staphylococcus aureus was expressed by 91% of
strains in a high-toxicity group [17]. A mutant strain with
deletions of b-hemolysin and catalase was significantly less
virulent to mice than the wild-type Staphylococcus aureus strain
[18]. We reported that Bc-SMase lysed sheep erythrocytes
containing large amounts of SM in the outer lipid layer of their
plasma membranes [19]. However, the enzyme is known not to
be lethal or cytotoxic. Bc-SMase belongs to a family of Mg
2+-
dependent neutral SMases (nSMase) that includes SMases
produced by Staphylococcus aureus, and Listeria ivanovii [20]. The
members of this family share a high degree of homology in
amino acid sequence [20,21,22]. However, the role of Bc-SMase
in the virulence of B. cereus remains controversial.
To investigate the relationship between Bc-SMase and B. cereus
infections, we examined the relationship between Bc-SMase and
the growth in vivo of clinical isolates of B. cereus.
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Pathogenicity of the Clinical Isolates of B. cereus
To investigate if B. cereus JMU-06B-31 and JMU-06B-1, isolated
from a patient with septicemia, and JMU-06B-35, isolated from
a patient with endophthalmitis, grow in mice in vivo, six- to eight-
week old male wild-type mice of the ICR mice were each injected
intraperitoneally with 5610
8 CFU of the clinical isolates or
ATCC21928, ATCC31429, and ATCC6464 isolated from soil.
Mice administered with the clinical isolates began to die after 12 h,
and all mice died within 30 h of the administration (Fig. 1A). Mice
injected with ATCC21928, ATCC31429, and ATCC6464 did not
die within 100 h (Fig. 1A). The number of microorganisms in the
blood of mice about 12 h after the administration of JMU-06B-31,
JMU-06B-35, and JMU-06B-1 was 300–400 CFU/100 mL,
whereas the ATCC strains were not detected in blood (Fig. 1B).
Production of Phospholipases by the Clinical Isolates and
the ATCC Strains of B. cereus
Phospholipases produced by bacteria such as Staphylococcus
aureus, Clostridium perfringens, and Helicobacter pylori are reported to
be associated with local infections and of importance in the
establishment of systemic diseases [4,16,23,24]. To analyze the
production of phospholipases by B. cereus, we measured the
amount of phospholipases produced by the clinical isolates and
the ATCC strains in Luria Broth medium. These strains were
cultured to an optical density at 620 nm of 0.8 in the medium.
The enzyme samples fractionated from the culture supernatants
were subjected to SDS-PAGE and Western blotting using anti-
Bc-SMase, -PCPLC, and -PIPLC antibodies. As shown in Fig. 2A,
large amounts (.5 mg/ml) of Bc-SMase, PCPLC, and PIPLC
were detected in the culture supernatants of the clinical isolates,
but very small amounts or undetectable levels in those of the
ATCC strains. These phospholipase C genes were detected in
every clinical and ATCC strain (Figure S1).
Next, we focused on the promoter sequence for the Bc-SMase
gene (smase) or PLC gene (plc) of clinical isolates and ATCC
isolates. The 235 and 210 promoter sequences of smase or plc
from clinical isolates were almost the same as those of ATCC
strains (Fig. 2B and 2C). In B. cereus, the transcriptional regulator
PlcR (Phospholipase C regulator) controls most known virulence
factors [25,26], and activates gene expression by binding to
a nucleotidic sequence called the ‘PlcR box’ [25]. As shown in
Fig. 2B and 2C, there was no clear difference in the sequence of
the PlcR box between clinical isolates and ATCC strains. In
addition, the amino acid sequence of Bc-SMase was highly
conserved in all strains (Figure S2).
Effect of Anti-phospholipases on Growth of B. cereus in
Mice
To provide clues regarding the growth of B. cereus in vivo, the
effect of anti-phospholipases on the growth of JMU-06B-35 in
mice was investigated. Mice were intraperitoneally injected with
the clinical isolate (JMU-06B-35, 5610
8 CFU) 2 h after the
intraperitoneally administration of 50 mg of anti-PCPLC, -PIPLC,
or -SMase antibody. The anti-Bc-SMase antibody completely
inhibited the growth of JMU-06B-35 in the bloodstream (Fig. 3A).
In addition, the mice injected with the anti-Bc-SMase antibody did
not die within 100 h (Fig. 3B). The administration of the anti-
PIPLC and -PCPLC antibodies had no effect on the growth and
lethality of JMU-06B-35 in mice (Fig. 3A and 3B). The
concentration of these antibodies was enough to neutralize the
activity of the three enzymes (10 mg) in vitro (data not shown). It
therefore appears that Bc-SMase plays an important role in the
propagation of B. cereus in vivo in our experimental condition.
To confirm the relationship between Bc-SMase and the growth
of B. cereus in vivo, we investigated the effect of immunization of
mice with Bc-SMase, PCPLC, or PIPLC on the death induced by
JMU-06B-35. The BALB/c mice were immunized with 25 mg
mixture of PCPLC, PIPLC, or Bc-SMase with Complete Freund’s
Figure 1. Lethal challenges with clinical isolates and ATCC strains of B. cereus. Mice were intraperitoneally administered with clinical isolates
and ATCC strains of B. cereus (3610
8 CFU/mouse). Clinical isolates; JMU-06B-31 (N), JMU-06B-35 (&), and JMU-06B-1 (m). ATCC strains; ATCC21928
(%), ATCC31429 (#), and ATCC6464 (g). A) Mice were monitored every five hours after the injection. The duration of the experiment was set at
100 h. B) The microorganisms in the blood of mice about 12 h after the administration of various strains were cultured on Luria Broth agar plates.
Values represent the mean 6 SEM; n=5 independent experiments. ND: not detected.
doi:10.1371/journal.pone.0038054.g001
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mice administered the clinical isolate began to die after
approximately 10 h, and all mice died within 30 h of the
administration (Fig. 3C). The survival rate of mice immunized
against Bc-SMase, PCPLC, or PIPLC was 100%, 0%, and 0%
30 h after infection, respectively (Fig. 3C).
Effect of Bc-SMase on Infection of Mice with ATCC Strain
Isolated from Soil
To investigate the role of Bc-SMase in B. cereus infections, we
examined the effect of Bc-SMase on B. cereus-induced death in
mice. The animals were intraperitoneally injected with mixtures of
ATCC21928 (5.0610
7 CFU/mouse), which did not produce Bc-
SMase in the culture supernatants, and various concentrations of
Bc-SMase. As shown in Fig. 4A, the increase in the rate of death
was dependent on the dose of Bc-SMase above 1.0 mg/mouse. On
administration of ATCC21928 and 5.0 mgo fBc-SMase, the death
rate was 100% within 30 h (Fig. 4A). Mice injected with
ATCC21928 or Bc-SMase alone survived after 100 h under the
experimental conditions (Fig. 4A). In addition, the number of
microorganisms in blood 12 h after the administration of the
mixture of ATCC21928 and 1.0 or 5.0 mgo fBc-SMase was 50–
100 and 300–400 CFU/100 ml, respectively (Fig. 4B). On the
other hand, the administration of ATCC21928 with PCPLC
(5.0 mg/mouse) or PIPLC (5.0 mg/mouse) resulted in no death
under the conditions (data not shown).
Figure 2. Expression of phospholipases and promoter sequences of smase from clinical isolates and ATCC strains of B. cereus. A) 50%
Ammonium sulfate precipitation fractions of the culture supernatants (1.0 mg protein) were subjected to SDS-PAGE and Western blotting using anti-
Bc-SMase, -PCPLC, and -PIPLC antibodies. Lane: 1, JMU-06B-31; 2, JMU-06B-35; 3, JMU-06B-1; 4, ATCC21928; 5, ATCC31429; 6, ATCC6464. A
representative result from one of three experiments is shown. B, C) The sequences of the promoter region of plc and smase from clinical isolates and
ATCC strains of B. cereus were aligned by the program T-Coffee [44]. Consensus sequences of regulatory elements are indicated in bold type. Gray
areas indicate nucleotide sequence differences.
doi:10.1371/journal.pone.0038054.g002
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received 50 mg of anti-SMase, -PCPLC, or -PIPLC antibodies and 2 h after the injection, were intraperitoneally administered B. cereus (JMU-06B-35). A)
B. cereus in blood was cultured on Luria Broth agar plates 12 h after the intraperitoneal injection. Values represent the mean 6 SEM; n=3
independent experiments. ND: not detected. B) Mice were monitored every five hours after the injection of B. cereus. The duration of the experiment
was set at 100 h. &, B. cereus; m, anti-PIPLC antibody + B. cereus;N, anti-PCPLC antibody + B. cereus; #, anti-Bc-SMase antibody + B. cereus. C) Mice
subcutaneously received an emulsion of the enzyme (Bc-SMase (#), PCPLC (N), or PIPLC (m)) and CFA (&) 2 times every 2 weeks. The immunized
mice received B. cereus (JMU-06B-35, 3610
8 CFU/mouse). The duration of the experiment was set at 100 h.
doi:10.1371/journal.pone.0038054.g003
Figure 4. Effect of Bc-SMase on the infection with B. cereus or B. subtilis. Mice received various concentrations of Bc-SMase and B. cereus
(ATCC21928, 5610
7 CFU/mouse). A) Mice were monitored every five hours after the injection. The duration of the experiment was set at 100 h. #, B.
cereus; %, 1.0 mg Bc-SMase; g, 5.0 mg Bc-SMase; m, 0.1 mg Bc-SMase + B. cereus;N, 1.0 mg Bc-SMase + B. cereus; &, 5.0 mg Bc-SMase + B. cereus.B )B.
cereus in blood was cultured on Luria broth agar plates. Values represent the mean 6 SEM; n=5 independent experiments.
doi:10.1371/journal.pone.0038054.g004
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cereus or B. subtilis in Mice
To investigate the effect of Bc-SMase on growth of B. cereus in
vivo, we transfected a vector expressing smase or the gene for
E53A (e53a), a variant which has little enzymatic activity [27]
(Table S1), into ATCC21928 or Bacillus subtilis (ISW1215), which
did not produce Bc-SMase in the culture supernatants. The
ammonium sulfate precipitation fraction of the culture superna-
tant fluids of these transfected strains was subjected to SDS-
PAGE and Western blotting using anti-Bc-SMase antibody. As
shown in Fig. 5A, these proteins (.5.0 mg/ml) were detected in
the culture supernatants of these transformants carrying smase or
e53a, but not in each microorganism transformed with empty
vector. When the mice intraperitoneally received ATCC21928 or
ISW1215 transformants carrying the smase, the microorganisms
were detected about 300–400 CFU/100 ml in bloodstream
(Fig. 5B). However, administration of these bacteria carrying
e53a had no effect on the growth of each microorganism in vivo
(Fig. 5B). The results showed that overexpression of Bc-SMase in
ATCC21928 or ISW1215 induced growth of these strains in
vivo. In addition, the survival rate 100 h after administration of
ATCC21928 transformants carrying the smase was approximately
50%, but that of ISW1215 was 100% (Fig. 5C).
Effect of Bc-SMase on Activation of Macrophages by
Peptidoglycan
Gonza ´lez Zorn et al. reported that the SMase from Listeria
ivanovii mediates bacterial escape from phagocytic cells [15]. The
activation of macrophages is known to be related to bactericidal
action in vivo. To investigate the effect of Bc-SMase on the
activation of macrophages, we assessed the effect of PGN, an
activator of macrophages, on macrophages treated with Bc-SMase.
Bc-SMase attenuated PGN-activated H2O2 generation and
phagocytosis of macrophages in a dose-dependent manner (Fig. 6A
and 6B). However, Bc-SMase had no effect on the release of TNF-
a induced by PGN from macrophages and induced no release of
lactate dehydrogenase (LDH) from the cells (Fig. 6C and 6D). It
therefore is likely that Bc-SMase specifically influences H2O2
generation and phagocytosis without impairing membranes of
macrophages, suggesting that treatment of macrophages with Bc-
SMase results in a change in function of the membranes. It was
thought that the frustrated phagocytosis may be dependent on the
formation of ceramide in macrophage membranes.
Localization of Ceramide in Membranes of Macrophages
Treated with Bc-SMase
To determine the amount of ceramide formed in the
macrophages treated with Bc-SMase, macrophages were in-
cubated with Bc-SMase at 37uC for 30 min. The lipids extracted
from the treated cells were phosphorylated by diacylglycerol
kinase from Escherichia coli, and developed by reverse-phase thin
Figure 5. Effect of overexpression of Bc-SMase on growth of B. cereus or B. subtilis in mice. A) B. cereus (ATCC21928) or B. subtilis (ISW1215)
was transfected with the plasmid carrying smase or e53a. A) 50% ammonium sulfate precipitation fractions of the culture supernatants (1.0 mg
protein) of each microorganism were subjected to SDS-PAGE and Western blotting using anti-Bc-SMase antibody. A representative result from one of
three experiments is shown. B, C) Mice intraperitoneally received B. cereus or B. subtilis transformants (1610
8 CFU/mouse) carrying empty vector
(vector), smase,o re53a. The microorganisms in the blood of mice about 12 h after the administration of these strains were cultured on Luria Broth
agar plates. Values represent the mean 6 SEM; n=5 independent experiments. C) Mice were monitored every five hours after the injection. The
duration of the experiment was set at 100 h.N, vector (B. cereus); &, smase (B. cereus); m, e53a (B.cereus); #, vector (B. subtilis); %, smase (B. subtilis);
g, e53a (B. subtilis).
doi:10.1371/journal.pone.0038054.g005
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treated with Bc-SMase increased in a dose-dependent manner
(Fig. 7A). Using confocal microscopy, Montes et al. found that
phospholipase C from P. aeruginosa caused the formation of
ceramide-rich domains in biological membranes [28]. We
reported that Bc-SMase induced the formation of ceramide-rich
domains in membranes of sheep erythrocytes and a decrease in
the fluidity of membranes, leading to destabilization under
physical stimulation [19]. We investigated whether treatment of
macrophages with Bc-SMase results in the local accumulation of
BODIPY-ceramide formed in membranes of cells preincubated
with BODIPY FL-C12-SM (BODIPY-SM). Fig. 7B (left) shows
that the fluorescent substance in membranes of macrophages
preincubated with BODIPY-SM was not localized. However,
when BODIPY-SM -incubated macrophages were treated with
Bc-SMase, the local accumulation of the fluorescent substance
was found on membranes of the cells, as shown by the white
arrows (Fig. 7B, right). To test whether the site where the
substance accumulates coincides with a ceramide-rich site,
BODIPY–SM-preincubated membranes treated with Bc-SMase
were analyzed using Cy3-labeled anti-ceramide antibody. As
shown in Fig. 7C, the distribution of the fluorescence of the
antibody was different from that of BODIPY–SM in the
untreated cells. In the case of BODIPY–SM-preincubated
macrophages treated with Bc-SMase, the location of the
fluorescence of Cy3-anti-ceramide antibody was consistent with
that of BODIPY, as shown in Fig. 7B, suggesting that BODIPY-
ceramide formed from BODIPY-SM in the macrophages treated
with Bc-SMase is mostly located in ceramide-rich domains. Klein
et al. reported that membrane fluidity of cells was evaluated by
measurement of lateral diffusion of fluorescence-labeled SM by
FRAP with a confocal laser microscopy [29]. A FRAP analysis
revealed that the recovery of effective diffusion for the
fluorescence of BODIPY in ceramide-rich domains of the
macrophages treated with Bc-SMase decreased to about 70–
80%, compared with that of BODIPY-SM in the untreated cells
Figure 6. Effect of Bc-SMase on activation of mouse macrophages. Mouse macrophages were incubated with or without Bc-SMase at 37uC
for 60 min (D), and then treated with PGN (5 mg/ml) for 60 min (A, B, C). H2O2 production, phagocytosis, TNF-a release, and LDH release were
measured as described in Materials and Methods. Values represent the mean 6 SEM; n=7;*P,0.01 compared with H2O2 production or phagocytosis
induced by PGN alone.
doi:10.1371/journal.pone.0038054.g006
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formation of ceramide from SM in membranes of macrophages
results in a decrease in the fluidity of membranes.
Discussion
The present study showed that clinical isolates of B. cereus, which
produced large amounts of Bc-SMase, from patients with sepsis
and endophthalmitis were lethal to mice. The production of Bc-
SMase from clinical isolates was greater than that from ATCC
strains under our culture conditions. B. cereus produces several
secreted toxins, the expression of which is controlled by the PlcR
[25,26]. A difference in protein level from PlcR regulated proteins
has been observed for pathogenic factors such as nonhemolytic
enterotoxin and hemolysin BL [30,31]. In addition, variations of
the InhA1, NprA, and HlyII, which regulation is independent on
PlcR, between pathogenic and nonpathogenic B. cereus strains has
also been observed [32]. In this study, the sequences of the PlcR
box in clinical isolates were almost the same as that in ATCC
strains. Therefore, it appears that various factors participate in the
pathogenic expression of B. cereus and production of Bc-SMase.
Bc-SMase enhanced the growth of B. cereus in the peritoneal
cavity, and in addition, invaded the bloodstream in mice, causing
death. Furthermore, overexpression of Bc-SMase in B. subtilis,a n
avirulent strain, induced growth in mice. The administration of
a mixture of ATCC21928 and Bc-SMase resulted in the death of
mice, but that of PIPLC or PCPLC did not. In addition, the loss
of PlcR-regulated factors, which include Bc-SMase, significantly
attenuated the severity of Bacillus endophthalmitis [10]. Further-
more, mice administered the anti-Bc-SMase antibody or immu-
nized with Bc-SMase were protected from the lethality of clinical
isolates of B. cereus. Callegan et al., reported that intraocular
infection with wild type B. cereus or isogenic mutants specifically
deficient in PIPLC or PCPLC resulted in similar degrees of
Figure 7. Effect of ceramide on activation of mouse macrophages. A) Mouse macrophages were incubated with various concentrations of
Bc-SMase at 37uC for 60 min. Ceramide was phosphorylated by 1, 2-diacylglycerol kinase and separated by reverse-phase TLC. Values represent the
mean 6 SEM; n=3;*P,0.01 compared with Bc-SMase-untreated cells. (B) Macrophages pretreated with BODIPY-SM were incubated without (left) or
with (right) Bc-SMase at 37uC for 60 min. (C) Mouse macrophages pretreated with BODIPY-SM were incubated with or without Bc-SMase at 37uC for
60 min. The cells were treated with paraformaldehyde, and stained with Cy3-coupled anti-ceramide anti-bodies. (D) Representative recovery curves
for the diffusion of BODIPY fluorescence following Bc-SMase treatment (broken line, ceramide-rich domain) or without treatment (solid line,
ceramide-poor domain) are shown. A representative result from one of ten experiments is shown.
doi:10.1371/journal.pone.0038054.g007
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retinal function [33,34]. These results suggested that Bc-SMase
plays an important role in the propagation of B. cereus in vivo.
Antibody and immunization against Bc-SMase protected mice
from B. cereus, suggesting Bc-SMase to be a candidate vaccine
against infectious diseases caused by B. cereus. Furthermore, it has
been reported that nSMase is secreted by several bacteria involved
in infectious diseases [17,18]. Drobnik et al. found that an increase
in ceramide levels mediated by nSMase in serum was associated
with sepsis-related mortality [35]. Gonzalez-Zorn et al. reported
that SMase from Listeria ivanovii was involved in avoiding
phagocytic vacuoles in the bovine epithelial-cell line MDBK
[15]. Heffernan et al. showed that the deletion of three
phospholipase (PIPLC, PCPLC, and SMase) genes was required
for the attenuation of virulence in a murine model of anthrax and
that these enzymes play an important role in the growth of Bacillus
anthracis in alveolar macrophages [36]. Lo et al. reported that
a combination of b-hemolysin immunization and Christie Atkins
Munch-Peterson factor neutralization cooperatively suppressed
the skin lesions caused by a coinfection of Staphylococcus aureus and
Propionibacterium acnes [37]. The result suggested the need for
immunotherapy targeting the interaction of Staphylococcus aureus
with a skin commensal. Therefore, our findings may provide
significant opportunities for the development of new vaccines
against infections caused by SMase-producing bacteria.
Treatment of macrophages with SMase resulted in a reduction
in the generation of H2O2 and phagocytosis of macrophages
induced by PGN, but no effect on the release of TNF-a and little
release of LDH under our experimental conditions. Therefore, it
appears that Bc-SMase specifically inhibits the activation of
macrophages induced by PGN without harmful effects on the
cells. The treatment with Bc-SMase is known to induce changes in
the lipid content of plasma membranes by generating ceramide
upon the cleavage of SM [38]. Ceramide is reported to promote
the coalescence of rafts, which have been termed ‘‘membrane
platforms’’ [39]. We reported that Bc-SMase induced the
formation of ceramide-rich domains in membranes of sheep
erythrocytes, and a decrease in the fluidity of membranes, leading
to destabilization under physical stimulation and finally the
disruption of erythrocytes [19]. The treatment of mouse macro-
phages with Bc-SMase caused the formation of ceramide, and
inhibition of the production of H2O2 and phagocytosis induced by
PGN. Treatment of macrophages with ceramide significantly
inhibited the generation of H2O2 and phagocytosis of macro-
phages activated by PGN, suggesting that the formation of
ceramide induced by Bc-SMase is closely related to a reduction in
the activation of macrophages. Nakabo and Pabst have reported
that C2- or C6-ceramide inhibited the release of superoxides from
monocytes primed with lipopolysaccharide, and induced the
secretion of small amounts of TNF-a and IL-1b [40]. The
treatment of macrophages with Bc-SMase resulted in the clustering
of ceramide recognized by a Cy3-anti-ceramide antibody.
Furthermore, using a confocal laser scanning microscope, we
found that the effective diffusion rate for BODIPY-ceramide at
ceramide-rich domains in macrophages treated with Bc-SMase
was reduced about 70%, compared with that for BODIPY-SM,
ceramide-poor domains, in control cells. Goni and Alonso
reported that the ceramide-rich domains formed a rigid phase in
membranes [28,41]. Therefore, it appears that the formation of
ceramide in macrophages treated with Bc-SMase results in
functional differences of the membranes through the coalescence
of ceramide-rich domains and formation of the interface between
rigid and fluid domains, leading specifically to inhibition of the
production of H2O2 and phagocytosis induced by PGN.
In conclusion, the hydrolysis of SM to form ceramide in the
macrophage membrane treated with Bc-SMase induced the
attenuation of membrane fluidity and the frustrated phagocytosis.
Bc-SMase plays a crucial role in the evasion from immune
response by macrophages during the early stages of infections of B.
cereus.
Materials and Methods
Strains
The clinical isolates of B. cereus (JMU-06B-31, JMU-06B-35, and
JMU-06B-1) were isolated at Jichi Medical University. These
isolates, obtained from patients diagnosed with Bacillus bacteremia
or endophthalmitis according to the CDC definition, were
identified and characterized as B. cereus, as described previously
[6]. The ATCC strains of B. cereus from soil (ATCC21928,
ATCC31429, ATCC6464) were purchased from DS Pharma
Biomedical, Tokyo, Japan. The characteristics of the clinical
isolates were reported previously [6].
Mice
Six- to eight-week old male wild-type mice of the ICR and
BALB/c strains (Nihon SLC, Japan) were used. Experimental
protocols were approved by the Institute Animal Care and Use
Committee at Tokushima Bunri University. The mice were
housed in plastic cage under controlled environmental conditions
(temperature 22uC, humidity 55%). Food and water were freely
available.
Detection of Genes Encoding Bc-SMase, PCPLC, and
PIPLC
The genomic DNA from various strains of B. cereus was
extracted with the bacteria genomicPrep Mini Spin kit from GE
healthcare (UK). The phospholipase C genes of the genomic DNA
were confirmed by PCR using the primer sets described below. Bc-
SMase primers were forward, 59-CAAATGGCCAATCGCT-
GAA-39, reverse, 59-GGTTCCTACGTACAGATGCTGGTG-
39. PCPLC primers were forward, 59-CTTTACAAAGCGTTG-
CATTTGCTC-39, reverse, 59-CAATCGCACGGTTTA-
CAATCCATA-39. PIPLC primers were forward, 59-ACCTGA-
TAGTATCCCGTTAGCACGA-39, reverse, 59-
CGAGCTCCATGGTCCATTTG-39.
DNA Cloning and Sequencing
The plc-smase region from B. cereus (JMU-06B-31, JMU-06B-35,
and JMU-06B-1, ATCC21928, ATCC31429, ATCC6464) was
obtained as a 2.1-kb DNA fragment by PCR using primer sets
described below. A1 forward primer: 59-GTATTCATTCAT-
TATTCACTGTG-39, A2 reverse primer: 59-CTACTTCATA-
GAAATAGTCGCCT-39. The fragment isolated from agarose
gels was cloned into the vector pGEM-T (Promega, USA).
Nucleotide sequencing of the cloned fragments was performed by
the dideoxy chain termination technique with a BigDye termina-
tor v1.1 cycle sequencing kit (Applied Biosystems, USA) using
M13 reverse and forward primers. The genetic sequence was
confirmed with an ABI3500 genetic analyzer (Applied Biosystems,
USA).
Site-directed Mutagenesis
The transformer site-directed mutagenesis kit (LA PCR in vitro
Mutagenesis Kit, Takara, Japan) was used with the primer E53A:
59-GTTATTTTAAATGCCGTGTTTGATAATAGC-39 to pre-
pare the modified plasmid. The genetic sequence of Bc-SMase in
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TM genetic
analyzer (Life technologies, USA).
Preparation of Bc-SMase and Variants
Bc-SMase and E53A were overexpressed in B. subtilis ISW1214
or B. cereus ATCC21928 transformed with the plasmid vector
pHY300PLK carrying smase or e53a. The expression and
purification of the recombinant Bc-SMase and variants were
performed as described previously [21].
Purification of PCPLC and PIPLC
PCPLC and PIPLC were overexpressed in B. subtilis ISW1214
transformed with pHY300PLK carrying the gene of PCPLC or
PIPLC cloned from B. cereus IAM1029. The PCPLC and PIPLC
were secreted into the culture medium. The 80% (w/v)
ammonium sulfate fraction of the Luria Broth was fractionated
by chromatography using a Cu
2+-column and then a DEAE-
Sepharose column. The purity of samples was verified using SDS-
PAGE, and staining with coomasie Brilliant Blue. The PCPLC
and PIPLC were observed as a single band at 28 kDa and 34 kDa,
respectively.
Preparation of Antibodies
Anti-Bc-SMase, -PCPLC, and -PIPLC antibodies were prepared
by immunizing rabbits with 100 mg of the purified phospholipases.
CFA (Difco, USA) (1.0 ml) was used for the preparation of
antigens. Two hypodermic booster injections were made. Antise-
rum was obtained 2 weeks after the last injection. Purification of
these antisera was performed using Ab-Rapid PuRe (Protenova,
Japan).
Immunization of Mice
Inbred 6–8-week old male BALB/c mice were immunized
subcutaneously two times at two-week intervals. The immunogens
were used 25 mg mixture of PCPLC, PIPLC, or Bc-SMase with
CFA.
ELISA Procedure
The purified recombinant PCPLC, PIPLC, or Bc-SMase was
diluted to 5 mg/ml in a carbonate buffer (0.05, pH 9.5) and used
to coat the wells of polystyrene plates (100 ml/well: Nunc-
Immuno plates with a Maxisorp surface) The plates were
incubated overnight at 4uC, and the next morning washed three
times with PBST (PBS/0.05% Tween-20). The remaining sites of
absorption were blocked by the addition of 200 ml/well in PBS
containing 3% BSA for 2 h at 37uC. The plates were washed
three times with PBST. Serum from each group of immunized
animals was serially diluted 2-fold (1:500 to 1:128,000) and
examined in triplicate wells (100 ml/well) of the blocked antigen-
coated plates and incubated for 1 h at 37uC. The plates were
then washed five times with PBST and further incubated at 37uC
for 1 h with HRP-conjugated anti-mouse IgG (1:2000). The
plates were washed five times with PBST and developed with
100 ml of ortho-pheylenediamine (0.4 mg/ml) in a fleshly pre-
pared citrate phosphate buffer (0.1 M, pH5.0) and H2O2
(0.4 mg/ml). The reaction was terminated by the addition of
50 ml of 2.5 N H2SO4/well. Absorbance was read at 492 nm
with a microtiter plate reader.
Determination of ELISA Titer by Endpoint Dilution
The serum was diluted 2-fold from 1:500 to 1:128,000, and an
absorbance value was determined for each dilution. The cut-off
value for the assay was calculated from the reference curve for the
control serum. The titer of immune serum was calculated as the
reciprocal of the highest dilution yielding a specific optical density
above the cut-off value. A significant (P,0.05) value of IgG
antibody against recombinant PCPLC, PIPLC, and Bc-SMase was
128,000, 64,000, and 64,000, respectively, when compared with
CFA-treated mouse serum.
Measurement of Cytokines
The concentration of TNF-a was determined with enzyme-
linked absorbent assay kits (R&D systems, USA).
Culture of Macrophages
Mouse macrophages were isolated from cells in peritoneal
exudates with 2 ml of phenol red-free RPMI1640 medium (Wako
Pure Chemical Industries, Japan) supplemented with 5% fetal
bovine serum (FBS) (Biowest, USA). After centrifugation at 1706g
for 10 min at 4uC, the cell pellet was resuspended in phenol red-
free RPMI1640 medium supplemented with 5% FBS. Adherent
macrophage monolayers were obtained by plating the cells in 96-
or 48-well plastic trays (Falcon, USA).
Preparation of sheep erythrocytes. Sheep erythrocytes
were suspended in 0.02 M Tris-HCl buffer (pH 7.5) containing
0.9% NaCl (TBS), and centrifuged at 1,1006g for 3 min. The
erythrocytes were washed by the centrifugation three times. The
number of erythrocytes was determined with a cell counter
(Celltac; Nihon Kohden, Japan).
Determination of Hemolytic Activity
Bc-SMase and E53A was incubated with sheep erythrocytes
(12610
10 cells/ml) in TBS at 37uC for 30 min, and the cells were
chilled at 4uC. The hemolysis of the erythrocytes was measured, as
described previously [42]. Hemolysis was expressed as a percentage
of the amount of hemoglobin released from 0.1 ml of erythrocytes
suspended in 0.4 ml of 0.4% NaCl.
Preparation of Liposomes
SM (Nacalai Tesque, Japan) from bovine brain and cholesterol
(1:1) in chloroform-methanol (2:1 v/v) were dried with N2 gas,
resuspended in TBS containing 0.1 M calboxyfluoroscein (CF).
The liposome suspensions were centrifuged at 22,0006g for
15 min at 4uC to remove the nonencapsulated marker, and
washed three times by centrifugation. The resulting liposomes
were suspended in 200 ml of TBS.
The SM-liposome-disruption activity. The SM-liposome-
disruption activity was evaluated at the amount of released-CF in
the test aliquot. The SM-liposomes in TBS containing
1 mM MgCl2 were incubated with Bc-SMase or E53A for
30 min at 37uC. The wavelengths for excitation and measurement
were 490 and 530 nm, respectively.
SMase Activity Assay
SMase activity was measured using an Amplex Red Sphingo-
myelinase assay kit (Invitogen, USA).
Measurement of Intracellular H2O2
Mouse macrophages (80% confluent in 48-well plates) isolated
from mouse peritoneal exudates were activated with 5 mg/ml
PGN (Sigma, USA) for 60 min in the presence of phenol red-free
RPMI1640 medium (supplemented with 5% FBS). H2O2 was
measured in the supernatants using an H2O2 assay kit (Oxis
International, USA).
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Phagocytic activity was determined by measuring the uptake of
fluorescent microspheres (Fluoresbrite Carboxylate Microspheres,
1.75 mm in diameter, Polysciences), as described [34]. Mouse
macrophages (80% confluent in 48-well plates) were stimulated by
PGN in the presence of 5.0610
5 fluorescent microspheres per ml.
After 3 h incubation, cells were washed, and fluorescent intensity
in the cells was determined with a fluorescence imaging analyzer
(FLA-1000, Fujifilm, Japan).
Measurement of LDH
LDH activity was determined with LDH assay kits (Wako Pure
Chemical Industries, Japan), according to the manufacturer’s
instructions.
Determination of Ceramide
Mouse macrophages were incubated with various concentra-
tions of Bc-SMase at 37uC for 60 min in phenol red-free
RPMI1640 medium supplemented with 5% FBS. The isolation
and the measurement of ceramide were performed as described
previously [42,43]. The ceramide, which is from bovine brain,
used as stimulants or standard was purchased from Sigma, USA.
Immunofluorescence Staining and Confocal Imaging
Mouse macrophages stained with 2 mM BODIPY-SM were
plated on 35-mm glass-bottomed dishes (MatTek, USA). The cells
were incubated with Bc-SMase in phenol red-free RPMI 1640
medium supplemented with 5% FBS at 37uC for 60 min, and the
reaction was stopped by 1.0% paraformaldehyde at room
temperature. For antibody labeling, the cells were incubated in
50 mM NH4Cl in phosphate- buffered saline (PBS) at room
temperature for 10 min. After being washed with PBS, the cells
were incubated in PBS containing 4% BSA at room temperature
for 60 min, followed by mouse Cy3-labeled-anti-ceramide anti-
body in PBS for 60 min.
Fluorescence Microscopy
A confocal fluorescence microscope (A1; Nikon, Japan) was
used. The excitation wavelength was 488 nm for BODIPY FL
C12-SM (Molecular probes, USA). The fluorescence signals were
simultaneously collected using NIS-Elements C (Nikon software,
Japan) into a channel using bandpass filters of 525/50. The
objective used in all experiments was a 606oil immersion, CFI
Plan Apo VC 606oil/1.40 objective (Nikon). The objective lens
was used with a zoom factor of 2. The experiments were
performed at room temperature.
Fluorescence Recovery after Photobleaching
Fluorescence recovery after photobleaching (FRAP), a technol-
ogy used to measure the lateral mobility of membranes, was
performed with a Nikon A1R confocal laser scanning microscope,
according to the manual. Mouse macrophages stained with 2 mM
BODIPY-SM were plated on 35-mm glass-bottomed dishes
(MatTek, USA). The photobleaching was performed in a 1.5 mm,
visually uniform region of the cell membranes. Bleaching was
performed with 5% laser intensity for a duration of approximately
1 s (10 scans of the laser) to achieve 20% bleaching of the
BODIPY fluorescence. After photobleaching, images were ac-
quired 200 times at 1 s intervals.
Statistics
Results were expressed as the mean 6 SEM. n equals the
sample size. Statistical comparisons were performed using an
unpaired t-test or one-way analysis of variance (ANOVA) with
Bonferroni correction. p Values less than 0.05 were considered
statistically significant.
Supporting Information
Figure S1 Detection of genes encoding Bc-SMase,
PCPLC, and PIPLC. The various strains of B. cereus were
determined for mRNA of Bc-SMase, PCPLC, and PIPLC.
(TIF)
Figure S2 The amino acid sequence alignment of Bc-
SMase from clinical isolates or ATCC strains. The amino
acid sequences of Bc-SMase from clinical isolates (JMU-06B-1, 31,
35) or ATCC strains (ATCC21928, 31429, 6464) were aligned by
the program T-Coffee. The sequences of signal peptide are
indicated in bold type. Gray areas indicate amino acid sequence
differences. The amino acid residues participating in the
enzymatic activity are shown by black circles.
(TIF)
Table S1 Biological activities of E53A. Activity (%) was
expressed as the percentage of each activity in the wild-type
enzyme. Each value is the mean of five experiments.
(DOCX)
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